阿替利珠单抗 (Tecentriq)

概览

Atezolizumab is a monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.

作用机制

Atezolizumab is a humanized IgG antibody that binds PD-L1, preventing its interaction with PD-1 and B7-1. Preventing the interaction of PD-L1 and PD-1 removes inhibition of immune responses such as the anti-tumor immune response but not antibody dependent cellular cytotoxicity.

适应症

Atezolizumab has approved indications for the following conditions: Non-Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer (SCLC) Hepatocellular Carcinoma (HCC) Melanoma Alveolar Soft Part Sarcoma (ASPS)

• Metastatic Alveolar Soft Part Sarcoma
• Metastatic Hepatocellular Carcinoma
• Metastatic Melanoma
• Metastatic Non-Small Cell Lung Cancer
• Metastatic Non-squamous Non Small Cell Lung Cancer
• Non-Small Cell Lung Carcinoma
• Nonsmall Cell Lung Cancer, Stage II
• Small Cell Lung Cancer (SCLC)
• Stage IIIA Non Small Cell Lung Cancer
• Triple-Negative Breast Cancer
• Unresectable Alveolar Soft Part Sarcoma
• Unresectable Hepatocellular Carcinoma (HCC)